Skip to main content
Premium Trial:

Request an Annual Quote

Syrrx, Pharmacia to Strike 3-D Proteomics Collaboration

NEW YORK, Jan. 23 - Drug-discovery company Syrrx is set to announce a collaboration with Pharmacia to determine the 3-D structure of proteins that may provide future drug targets.


The two firms will focus on drugs to treat cancer, inflammation, infectious disease, among other disorders. Under the agreement, Pharmacia will pay a technology access fee, R&D funding, and success payments. The pharmaceutical company may also take an equity stake in Syrrx.


Financial details of the agreement, which will be announced on Thursday, were not revealed.


Pharmacia also plans to deploy Syrrx's technology platform internally, where it is expected to improve and streamline the effort to ascertain protein structures. Syrrx's technologies are designed to speed the labor-intensive process of x-ray crystallography.


According to Syrrx CEO Wendell Wierenga, the effort is the first large-scale, multi-family structural proteomics effort adopted by a major pharmaceutical company.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.